# Ampersand Capital Partners

> Ampersand Capital Partners is a Boston-based, middle-market private equity firm founded in 1988 that invests in the 'picks and shovels' of healthcare - the laboratory products, contract manufacturers, pharma services and diagnostics companies that supply the scientists chasing the next breakthrough medicine. With roughly $3 billion under management and a founder-friendly playbook of majority and minority stakes, Ampersand builds specialist suppliers into category leaders across North America, Europe and Asia.

- **Founded:** 1988
- **Headquarters:** Boston, United States
- **Founders:** Richard A. Charpie (Founder & Managing Partner)
- **Team size:** ~56 employees
- **Products:** Laboratory Products, Laboratory Services, Contract Manufacturing (CDMO), Pharma Services, Specialty Products
- **Notable:** Named a GrowthCap Top Private Equity Firm of 2025, Named a GrowthCap Top Growth Equity Firm of 2025, Ranked #6 Growth Capital Fund globally in the HEC Paris-Dow Jones ranking

## Products & services

- **Laboratory Products** — Growth investments in makers of instruments, reagents, consumables and research tools used across life sciences labs.
- **Laboratory Services** — Backing genomics, bioanalytical, diagnostics and testing services companies that support drug development and clinical research.
- **Contract Manufacturing (CDMO)** — Building contract development and manufacturing organizations across biologics, cell and gene therapy, and drug product.
- **Pharma Services** — Investing in outsourced service providers spanning CRO, CMC, formulation and clinical supply.
- **Specialty Products** — Specialty pharma and healthcare products companies with differentiated, mission-critical offerings.
- **Ampersand 2026 (AMP-26) Fund** — Twelfth primary fund, closed at its $1.5 billion hard cap in a single, oversubscribed close.

## Achievements

- Named a GrowthCap Top Private Equity Firm of 2025
- Named a GrowthCap Top Growth Equity Firm of 2025
- Ranked #6 Growth Capital Fund globally in the HEC Paris-Dow Jones ranking
- Named a top founder-friendly investor by Inc. Magazine for four consecutive years
- Cited among top-performing private equity fund managers in the Americas by Preqin
- Closed AMP-26 at its $1.5 billion hard cap in a single, oversubscribed close in May 2026
- Built and exited category leaders including Brammer Bio (to Thermo Fisher), GENEWIZ (to Brooks Automation) and Nexcelom Bioscience (to PerkinElmer)

## Latest updates

- **2026-05** — Closed the oversubscribed Ampersand 2026 (AMP-26) fund at its $1.5 billion hard cap in a single close, its twelfth primary fund since 1992.
- **2025-09** — Named a GrowthCap Top Private Equity Firm and Top Growth Equity Firm of 2025.
- **2026-01** — Portfolio CDMO Alcami expanded through the acquisition of Tjoapack.

## Links

- Website: https://ampersandcapital.com
- LinkedIn: https://www.linkedin.com/company/ampersand-capital-partners
- YouTube: https://www.youtube.com/@AmpersandCapitalPartners

---

Profile page: https://yespress.io/ampersand-capital-partners
Published by YesPress — https://yespress.io
Last updated: 2026-08-15